FGF13, fibroblast growth factor 13, 2258

N. diseases: 167; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0028754
Disease: Obesity
Obesity 		0.020 Biomarker disease BEFREE <b>Results:</b> FGF7, FGF10, and FGF13 were significantly associated with obesity (P = 0.02). 30992111 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis 		0.030 Biomarker disease BEFREE 18-kDa FGF-2 aggravated the inflammatory reaction of atherosclerosis. 29466783 2018
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.020 Biomarker disease BEFREE 18-kDa FGF-2 aggravated the inflammatory reaction of atherosclerosis. 29466783 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE 4E facilitates the synthesis of two powerful tumor angiogenic factors (VEGF and FGF-2) by selectively enhancing their translation. 10443829 1999
CUI: C0023487
Disease: Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia 		0.010 AlteredExpression disease BEFREE APL expressed high levels of FGF13 and FGFR1 as well as two potent angiogenic factors, HGF and VEGF. 15674361 2005
CUI: C1859592
Disease: ATRICHIA WITH PAPULAR LESIONS
ATRICHIA WITH PAPULAR LESIONS 		0.010 AlteredExpression disease BEFREE APL expressed high levels of FGF13 and FGFR1 as well as two potent angiogenic factors, HGF and VEGF. 15674361 2005
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.080 AlteredExpression group BEFREE Malignant tumors with deregulated FGF-2 expression such as prostate cancer are also frequently aneuploid. 23243019 2013
CUI: C0025202
Disease: melanoma
melanoma 		0.020 Biomarker disease BEFREE FGF-2 obviously has importance as a melanocyte survival factor and probably also in the development of malignant melanoma. 10417628 1999
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.020 AlteredExpression disease BEFREE FGF-2 expression did correlate with a short doubling time as well as with potent anchorage-independent growth of NSCLC cell lines. 10495436 1999
CUI: C0023473
Disease: Myeloid Leukemia, Chronic
Myeloid Leukemia, Chronic 		0.010 Biomarker disease BEFREE FGF-2 abnormalities in B cell chronic lymphocytic and chronic myeloid leukemias. 11236938 2001
CUI: C0003873
Disease: Rheumatoid Arthritis
Rheumatoid Arthritis 		0.020 Biomarker disease BEFREE FGF-2 may prove to be a possible therapeutic target to treat subjects with RA. 11751992 2002
CUI: C0149925
Disease: Small cell carcinoma of lung
Small cell carcinoma of lung 		0.010 Biomarker disease BEFREE FGF-2 can thus protect SCLC cells from chemotherapeutic drugs by modulating IAP levels via posttranscriptional regulation, providing a mechanism for postmitochondrial survival signaling by the MEK/mitogen-activated protein kinase pathway. 14560006 2003
CUI: C0002793
Disease: Anaplasia
Anaplasia 		0.020 AlteredExpression disease BEFREE FGF-2 and laminin 5 expression were found throughout benign and atypical dedifferentiation in mammary tissue samples and were lost primarily with transformation to invasive cancer.FGFR1 was expressed in all cell types. 16996573 2007
CUI: C0677898
Disease: invasive cancer
invasive cancer 		0.010 AlteredExpression phenotype BEFREE FGF-2 and laminin 5 expression were found throughout benign and atypical dedifferentiation in mammary tissue samples and were lost primarily with transformation to invasive cancer.FGFR1 was expressed in all cell types. 16996573 2007
CUI: C0036572
Disease: Seizures
Seizures 		0.030 AlteredExpression phenotype BEFREE Fgf-2 overexpression increases excitability and seizure susceptibility but decreases seizure-induced cell loss. 19052202 2008
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE FGF-2 was downregulated in tumor tissue. 19245594 2009
CUI: C0344460
Disease: Carcinoma ex pleomorphic adenoma
Carcinoma ex pleomorphic adenoma 		0.010 AlteredExpression disease BEFREE FGF-2 is overexpressed in myoepithelial cells of carcinoma ex-pleomorphic adenoma in situ structures. 20514456 2010
CUI: C3714756
Disease: Intellectual Disability
Intellectual Disability 		0.010 Biomarker group BEFREE FGF13-deficient mice also exhibit weakened learning and memory, which is correlated to XLMR patients' intellectual disability. 22726441 2012
CUI: C0025362
Disease: Mental Retardation
Mental Retardation 		0.010 Biomarker disease BEFREE FGF13-deficient mice also exhibit weakened learning and memory, which is correlated to XLMR patients' intellectual disability. 22726441 2012
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.040 Biomarker disease BEFREE FGF-2 disrupts mitotic stability in prostate cancer through the intracellular trafficking protein CEP57. 23243019 2013
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.040 Biomarker disease BEFREE FGF-2 disrupts mitotic stability in prostate cancer through the intracellular trafficking protein CEP57. 23243019 2013
CUI: C0029456
Disease: Osteoporosis
Osteoporosis 		0.010 GeneticVariation disease BEFREE FGF-2 Gene Polymorphism in Osteoporosis among Guangxi's Zhuang Chinese. 28653999 2017
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis 		0.030 AlteredExpression disease BEFREE FGF-2 levels were similar between patients with or without plaque at baseline (79 versus 88 pg/ml), but lower in patients with atheromatosis progression after 2 years (78 versus 98 pg/ml; <i>P</i><0.01). 29519952 2018
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.380 Biomarker phenotype BEFREE FGF-2 appears as a promising candidate for monitoring the efficacy of emboli- zation in patients with osteolytic metastases. 29534588 2019
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm 		0.010 Biomarker group BEFREE FGF-2 appears as a promising candidate for monitoring the efficacy of emboli- zation in patients with osteolytic metastases. 29534588 2019